Related Experiment Video

Updated: Aug 14, 2026

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
11:59

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

Does heterozygous beta-thalassemia confer a protection against coronary artery disease?

Stergios Tassiopoulos1, Spyros Deftereos, Kostas Konstantopoulos

  • 1First Department of Internal Medicine, University of Athens Medical School, Laiko Hospital, Athens, Greece.

Annals of the New York Academy of Sciences
|December 13, 2005
PubMed

Insights

Individuals with beta-thalassemia trait show a reduced risk of advanced coronary artery disease. This finding suggests a potential protective effect against atherosclerosis in patients with this genetic condition.

Area of Science:

  • Cardiology
  • Genetics
  • Hematology

Background:

  • Stable angina pectoris is a common cardiovascular condition.
  • Advanced coronary artery disease (aCAD) involves significant arterial stenosis.
  • The beta-thalassemia trait is a genetic blood disorder.

Purpose of the Study:

  • To investigate the potential protective effect of the beta-thalassemia trait against advanced coronary artery disease.
  • To analyze the association between beta-thalassemia heterozygosity and the risk of aCAD.

Main Methods:

  • Study included 638 patients with symptoms or ECG findings of stable angina pectoris.
  • Coronary arteriography was performed to assess coronary artery disease.
  • Hemoglobin electrophoresis identified patients with the beta-thalassemia trait.
  • Logistic regression analysis was used to evaluate the association.

Main Results:

  • Established risk factors like smoking, hypertension, hypercholesterolemia, and diabetes were reconfirmed.
  • Beta-thalassemia heterozygosity was associated with a significantly reduced risk of aCAD (odds ratio 0.39).
  • The protective effect may be linked to altered lipoprotein profiles and blood rheology.

Conclusions:

  • The beta-thalassemia trait appears to confer a protective effect against advanced coronary artery disease.
  • Further research into lipoprotein and blood rheology may elucidate the mechanisms behind this protection.

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...